Recent searches
Search options
Administered by:
RT @manjuggm@twitter.com
Tagging Drs @PrajnanDasMD@twitter.com @DrJZell@twitter.com @skopetz@twitter.com @CathyEngMD@twitter.com @JeanneTie@twitter.com @pashtoonkasi@twitter.com @IbrahimSahinMD1@twitter.com
#ctDNA #CRCSM
https://www.ejcancer.com/article/S0959-8049(22)01803-2/fulltext https://twitter.com/CrcTrialsChat/status/1615060410176049160
: European Journal of CancerctDNA-Response evaluation criteria in solid tumors- – a new measure in medical oncologyIn the metastatic setting, most decisions during systemic palliative therapies are
based on the imaging-based Response Evaluation Criteria in Solid Tumors (RECIST),
which is, however, known to be a suboptimal surrogate marker for the clinical outcome
overall survival. Over the past decade, research has brought focus to the potential
of circulating tumour DNA in cancer. However, at present, there is no generally accepted
classification of quantitative changes during the treatment course, and prospective
investigations can therefore not be validated.